MTIP AG Opens EverHealth Fund, an Evergreen ELTIF for European Healthcare Technology

MTIP AG has launched the EverHealth Fund, an evergreen private equity strategy for European healthcare technology structured as a Luxembourg-domiciled European Long-Term Investment Fund, and the fund is now open for subscriptions. startupticker.ch published the announcement on November 2, 2026.

How the EverHealth Fund Is Built

MTIP AG said EverHealth combines new direct investments, opportunities from within its existing ecosystem and selected secondaries to build a diversified portfolio of European healthcare technology investments over time. The fund invests across three areas: direct investments in European healthcare technology companies, follow-on investments in selected MTIP portfolio companies, and selected secondary opportunities across healthcare and technology.

EverHealth is structured as a semi-liquid, open-ended fund with no fixed end date. It offers EUR and CHF share classes, fully funded shares without traditional capital calls, and quarterly subscription and redemption opportunities. MTIP said the open-ended structure is designed to offer greater flexibility in accessing private equity.

Dr. Christoph Kausch, Managing Partner at MTIP, said: "The launch of the MTIP EverHealth Fund marks an important next step for MTIP: it allows us to bring our specialist healthcare technology investment strategy into an evergreen format and provide investors with a flexible way to access private equity." Kausch added that the investment approach remains unchanged: "identifying attractive healthcare technology businesses across Europe and partnering with their management teams to support long-term growth."

MTIP said the fund builds on more than a decade of experience investing in healthcare technology. The firm has focused on partnering with healthcare technology companies across Europe since 2014.

MTIP's Recent Deal Activity

According to akta.pro company records, MTIP made a strategic growth equity investment in Verifarma, a Spain-headquartered provider of pharmaceutical serialization, traceability and regulatory compliance solutions, in March 2026. In January 2026 the firm sold a majority stake in Trialbee to Varsity Healthcare Partners while retaining a minority position, realizing returns after Trialbee's revenue grew more than 18x during MTIP's ownership. In July 2025 MTIP exited portfolio company Cynerio via an acquisition by Axonius, a cybersecurity firm valued at $2.6 billion. The same records show MTIP Fund II closed above its $225 million target at $250 million in capital commitments and is designated a "dark green" Article 9 fund under the EU Sustainable Finance Disclosure Regulation, and that MTIP's investments span 12 European countries.